Celtek Bioscience

Overcome the Barrier

HomeTechnologiesProductsServicesContact Information


Celtek has developed a highly effective, patent-protected peptide agent (CB5005) that shows specific activity in promoting significant levels of apoptosis of androgen-independent prostate cancer cells, either alone or in combination with conventional chemotherapeutic drugs, such as cisplatin or etoposide.

CB5005, by virtue of its mechanism of action, also has other therapeutic uses. Celtek is currently investigating the various therapeutic uses for CB5005 and is actively developing it as a therapeutic agent for the treatment of cancer and other human diseases. CB5005’s first target is androgen-independent prostate cancer, prostate cancer being the second leading cause of cancer-related deaths in the United States.

The company has successfully obtained funding for its research and development activities from the National Institutes of Health. Celtek welcomes capital investment and joint development partnerships to obtain FDA approval of CB5005 and market the product for its many uses, starting with prostate cancer therapy.

In addition to CB5005, Celtek team is also working on R&D of other cell-permeable peptide-based preclinical drug compounds, which may be therapeutically effective for a variety of human diseases.